TOLREMO therapeutics Completes USD 39 Million Series A Financing Round

TOLREMO’s mission is to stop non-genetic cancer drug resistance as it emerges by dismantling cancer's earliest defenses to targeted therapies, thus surmounting a universal challenge for current and future targeted treatments. "Cancer drug resistance is a major impediment to the long-term survival of patients and is most often addressed in the later stages of treatment when genetic mutations have already rendered the cancer permanently impervious to therapy. At TOLREMO, we have developed TT125-802 to specifically block early, non-genetic resistance pathways to targeted treatments. In combination with therapeutic agents TT125-802 has the potential to prevent therapy evasion and significantly improve treatment durability," said Stefanie Flückiger-Mangual, PhD, co-founder and Chief Executive Officer of TOLREMO.

Strategic investment from Pierre Fabre Invest

BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest – the investment arm of the second largest private French pharmaceutical group -, as well as existing investors. Francesco Hofmann, PhD, Head of R&D for Medical Care at Pierre Fabre Laboratories, joined TOLREMO's Scientific Advisory Board. "TOLREMO has a very distinct scientific approach to providing rational combination therapies that pre-emptively address the problem of drug resistance in cancer treatment. This new investment is very consistent with our renewed strategy to focus our R&D portfolio on targeted therapies," commented Francesco Hofmann, Head of R&D for Medical Care at Pierre Fabre Laboratories and new member of TOLREMO's Scientific Advisory Board.

In conjunction with the financing, Julie M. Cherrington, PhD, an experienced life science executive with a track record of successfully bringing drugs into the clinic through to commercialization, has been appointed as Chair of the Board of Directors. Julie M. Cherrington is a seasoned biotech industry leader and holds board roles across several firms. In addition, she is a Venture Partner at Brandon Capital Partners. Dr. Cherrington has a proven track record as a company leader in her roles as CEO and R&D head at numerous companies.

First-in-human study in solid tumor indications

TOLREMO’s lead candidate, TT125-802, is an orally available small molecule CBP/p300 bromodomain inhibitor that blocks critical transcriptional resistance pathways responsible for cancer’s early escape mechanisms to targeted therapies. The proceeds of the Series A round will support the initiation of a Phase 1 monotherapy dose escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and early signs of efficacy, including biological activity of TT125-802, in a range of solid tumor indications. Stepwise, TOLREMO will then advance to evaluating TT125-802 in combination with targeted therapies such as KRAS, EGFR or AR inhibitors in specific advanced solid tumor indications.